Company Overview of Fresenius Kabi USA, LLC
Fresenius Kabi USA, LLC, an integrated pharmaceutical company, develops, manufactures, and markets injectable pharmaceutical products for customers in North America. The company primarily focuses on the anesthetic/analgesic, anti-infective, critical care, and oncology markets for use in hospitals, long-term care facilities, alternate care sites, and clinics. It manufactures various dosages and formulations in the areas of cardiac care, dialysis, emergency, intensive care, OB/GYN, operating room, oncology, orthopedics, pediatrics, psychiatry, and radiology. The company was formerly known as APP Pharmaceuticals, LLC and changed its name to Fresenius Kabi USA, LLC in August 2012. The company wa...
1501 East Woodfield Road
Suite 300 East
Schaumburg, IL 60173-5837
Founded in 1996
Key Executives for Fresenius Kabi USA, LLC
President and Chief Executive Officer
Executive Vice President and Chief Financial Officer
Chief Operating Officer and Executive Vice President
Chief Scientific Officer and Executive Vice President
Executive Vice President and General Counsel
Compensation as of Fiscal Year 2014.
Fresenius Kabi USA, LLC Key Developments
Fresenius Kabi Receives from FDA for Kabiven® and Perikabiven®
Aug 26 14
Fresenius Kabi announced it has received approval from the U.S. Food and Drug Administration for Kabiven® and Perikabiven®, parenteral nutrition (PN) products in a three-chamber bag – the only container of its kind available in the United States. Kabiven and Perikabiven are intravenously infused solutions of lipids, dextrose, amino acids and electrolytes in three-chamber parenteral nutrition bags that efficiently deliver these nutrients in volumes and concentrations that meet the nutritional needs of most patients. The unique three-chamber bag simplifies the delivery of parenteral nutrition by providing a premixed solution that is shelf-stable until activated for patient use. Outside the United States, Kabiven is sold in more than 85 countries and has been used to treat approximately 9 million patients since its initial marketing authorization in 1999.
Cadence Pharmaceuticals, Inc. Enters into Settlement Agreement with Fresenius Kabi USA, LLC
Aug 6 14
Cadence Pharmaceuticals Inc. has entered into settlement and license agreements with Fresenius Kabi USA, LLC, resolving pending patent litigation involving OFIRMEV(R) (acetaminophen) injection. The companies are not disclosing specific terms of the settlement and license agreements. Cadence had filed suit against Fresenius Kabi in January 2013. Other details of the settlement are confidential, and the settlement is subject to submission to the Federal Trade Commission and the U.S. Department of Justice. The settlement and license agreements will become effective upon the entry by the U.S. District Court of an order dismissing with prejudice the litigation with respect to Fresenius Kabi.
Fresenius Kabi USA Announces Immediate Availability Acetylcysteine Solution, USP, 20% 4 mL Vial
Feb 24 14
Fresenius Kabi USA announced it has launched for immediate availability Acetylcysteine Solution, USP, 20% 4 mL vial for inhalation (mucolytic agent) or oral administration (acetaminophen antidote). Acetylcysteine Solution, USP, has been on the U.S. Food and Drug Administration and the American Society of Health-System Pharmacists' drug shortage lists since 2011. The availability of Acetylcysteine Solution, USP 20% in 4 mL vials is the most recent extension of this product line for Fresenius Kabi.
Similar Private Companies By Industry
Recent Private Companies Transactions